Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging?

被引:23
作者
Jacquy, C
Lambert, F
Soree, A
Van Daele, S
Heusterspreute, M
Bosly, A
Ferrant, A
Parma, J
Bron, D
Martiat, P
机构
[1] Free Univ Brussels, Inst Jules Bordet, Dept Hematol, B-1000 Brussels, Belgium
[2] Erasme Univ Hosp, Ctr Med Genet, B-1070 Brussels, Belgium
[3] Univ Louvain, Sch Med, Hematol Unit, Yvoir, Belgium
[4] Lab Clin Mol Biol, Yvoir, Belgium
关键词
lymphoma; PBSC; residual disease;
D O I
10.1038/sj.bmt.1701637
中图分类号
Q6 [生物物理学];
学科分类号
071011 [生物物理学];
摘要
Intensification using peripheral blood stem cells collected after chemotherapy followed by growth factors is being increasingly investigated as an alternative to conventional chemotherapy for mantle cell non-Hodgkin lymphoma, We investigated 14 grades III-IV, t(11;14)-positive cases for contamination of PBSC collected after a polychemotherapy regimen followed by G-CSF, Patients were first treated with a polychemotherapy regimen There were four CR, seven PR, two refractory and one early death. Seven patients have been transplanted, in whom PBSC were mobilized, using either cyclophosphamide/VP16 or Dexa-BEAM followed by G-CSF, For all patients, whether actually autografted or not, PB cells were tested at the time of regeneration on G-CSF after the first polychemotherapy or after the mobilizing regimen. PCR evaluation of contamination was performed first by a semi-quantitative approach, using serial dilutions of initial DNA, then confirmed using a limiting-dilution analysis. Two patients were not informative (one early death and one without an available molecular marker). PB cells collected at regeneration contained at least one log more lymphoma cells than steady-state blood or marrow, apart from in two cases. Moreover, where a mobilizing treatment diminished tumor burden in the patient, at the same time it increased PB contamination in most cases, We conclude that advanced mantle cell NHL appears to be largely resistant to significant in vivo purging by conventional chemotherapy, Where treatment brings benefits by reducing tumor load, it may at the same time negate it by mobilizing malignant cells into the collections used to intensify. Although the clonogenic potential of this massive infiltration is unknown (only gene marking studies could provide a definitive answer regarding the source of relapses), strategies aimed at reducing the level of contamination in the graft should be considered when designing future protocols.
引用
收藏
页码:681 / 686
页数:6
相关论文
共 30 条
[1]
Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation [J].
Adkins, D ;
Brown, R ;
Goodnough, LT ;
Khoury, H ;
Popovic, W ;
DiPersio, J .
BONE MARROW TRANSPLANTATION, 1998, 21 (01) :97-99
[2]
Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease [J].
Andersen, NS ;
Donovan, JW ;
Borus, JS ;
Poor, CM ;
Neuberg, D ;
Aster, JC ;
Nadler, LM ;
Freedman, AS ;
Gribben, JG .
BLOOD, 1997, 90 (10) :4212-4221
[3]
AUBIN J, 1995, LEUKEMIA, V9, P470
[4]
Bigoni R, 1996, ONCOGENE, V13, P797
[5]
High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas:: a single center experience on 18 patients [J].
Blay, JY ;
Sebban, C ;
Surbiguet, C ;
Ouachée, M ;
Philip, I ;
Philip, T ;
Biron, P .
BONE MARROW TRANSPLANTATION, 1998, 21 (01) :51-54
[6]
Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO
[7]
2-Z
[8]
Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting [J].
Corradini, P ;
Astolfi, M ;
Cherasco, C ;
Ladetto, M ;
Voena, C ;
Caracciolo, D ;
Pileri, A ;
Tarella, C .
BLOOD, 1997, 89 (02) :724-731
[9]
Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma [J].
Dreger, P ;
vonNeuhoff, N ;
Kuse, R ;
Sonnen, R ;
Glass, B ;
Uharek, L ;
Bartels, H ;
Loffler, H ;
Schmitz, N .
ANNALS OF ONCOLOGY, 1997, 8 (04) :401-403
[10]
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission [J].
Freedman, AS ;
Neuberg, D ;
Gribben, JG ;
Mauch, P ;
Soiffer, RJ ;
Fisher, DC ;
Anderson, KC ;
Andersen, N ;
Schlossman, R ;
Kroon, M ;
Ritz, J ;
Aster, J ;
Nadler, LM .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :13-18